Supplementary table S2 from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups

Autor: Ellen C. Zwarthoff, Torben F. Ørntoft, Per-Uno Malmström, Núria Malats, Francisco X. Real, Joost L. Boormans, Kerstin Junker, Jørgen B. Jensen, Astrid C. Petersen, Niels Harving, Arndt Hartmann, Karin Mogensen, Gregers G. Hermann, Marc-Oliver Grimm, Marcus Horstmann, Tatjana Simic, Tobias Maurer, Bastian Keck, Ulrika Segersten, Willemien Beukers, Naeromy Y.C. Welvaart, Ferran Algaba, Lars Dyrskjøt, Kirstin A. van der Keur, Kim E.M. van Kessel

Supplementary Table S2. Cut-offs for dichotomization of the methylation marker results were chosen based on the desired sensitivity-specificity trade-off for progression to MIBC as visualized by the receiver-operating characteristic curve (ROC curve)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30adab21fbd59d86268d22a20ae141de
https://doi.org/10.1158/1078-0432.22464563.v1

Data from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups

Autor: Ellen C. Zwarthoff, Torben F. Ørntoft, Per-Uno Malmström, Núria Malats, Francisco X. Real, Joost L. Boormans, Kerstin Junker, Jørgen B. Jensen, Astrid C. Petersen, Niels Harving, Arndt Hartmann, Karin Mogensen, Gregers G. Hermann, Marc-Oliver Grimm, Marcus Horstmann, Tatjana Simic, Tobias Maurer, Bastian Keck, Ulrika Segersten, Willemien Beukers, Naeromy Y.C. Welvaart, Ferran Algaba, Lars Dyrskjøt, Kirstin A. van der Keur, Kim E.M. van Kessel

Purpose: The European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC) recommend risk stratification based on clinicopathologic parameters. Our aim was to investigate the added value of biomarkers to improve ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff6f823fded43852feeeb7d38f3e444
https://doi.org/10.1158/1078-0432.c.6525746

Supplementary table S4 from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups

Autor: Ellen C. Zwarthoff, Torben F. Ørntoft, Per-Uno Malmström, Núria Malats, Francisco X. Real, Joost L. Boormans, Kerstin Junker, Jørgen B. Jensen, Astrid C. Petersen, Niels Harving, Arndt Hartmann, Karin Mogensen, Gregers G. Hermann, Marc-Oliver Grimm, Marcus Horstmann, Tatjana Simic, Tobias Maurer, Bastian Keck, Ulrika Segersten, Willemien Beukers, Naeromy Y.C. Welvaart, Ferran Algaba, Lars Dyrskjøt, Kirstin A. van der Keur, Kim E.M. van Kessel

Supplementary Table S4. Number of patients progressing to MIBC and person-time per risk group. Suggested risk groups are based on a combination of GATA2 methylation and FGFR3 mutation status for EAU high risk tumors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5051e9ddc8f5dac55f6b61d95e675c5e
https://doi.org/10.1158/1078-0432.22464557.v1

FGFR3 , TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study

Autor: Jørgen Bjerggaard Jensen, Raju Kandimalla, Francisco X. Real, Lars Dyrskjøt, Núria Malats, Torben F. Ørntoft, Ellen C. Zwarthoff, José A. Lorente, Kirstin A. van der Keur, Per-Uno Malmström, Joost L. Boormans, Ewout W. Steyerberg, Willemien Beukers, Ulrike Segersten, Yvonne Vergouwe

Publikováno v: Journal of Urology, 197(6), 1410-1417. Elsevier Inc.
Beukers, W, van der Keur, K A, Kandimalla, R, Vergouwe, Y, Steyerberg, E W, Boormans, J L, Jensen, JB, Lorente, J A, Real, F X, Segersten, U, Orntoft, T F, Malats, N, Malmström, P-U, Dyrskjot, L & Zwarthoff, E C 2017, ' FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study ', Journal of Urology, vol. 197, no. 6, pp. 1410-1418 . https://doi.org/10.1016/j.juro.2016.12.096

PURPOSE: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 were investigated as a diagnostic urinary marker combination during followup of patients with primary nonmuscle invas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb4d231df6598a98ef24c14b913936e2
https://doi.org/10.1016/j.juro.2016.12.096

Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

Autor: Angela A.G. van Tilborg, Lars Dyrskjøt, Kirstin A. van der Keur, Cheno Abas, Enrique Carrillo-de Santa Pau, Torben F. Ørntoft, Willemien Beukers, Marta Flández, Miriam Marqués, Roy Masius, Irene Lurkin, Josep Lloreta, Mirari Marquez, José A. Lorente, Ana Sagrera, Núria Malats, Ellen C. Zwarthoff, Manolis Kogevinas, Ewout W. Steyerberg, Yves Allory, Alfredo Carrato, Marcel Vermeij, Francisco X. Real, Tahlita C.M. Zuiverloon

Publikováno v: European Urology; Vol 65
Allory, Y, Beukers, W, Sagrera, A, Flández, M, Marqués, M, Márquez, M, van der Keur, K A, Dyrskjot, L, Lurkin, I, Vermeij, M, Carrato, A, Lloreta, J, Lorente, J A, Carrillo-de Santa Pau, E, Masius, R G, Kogevinas, M, Steyerberg, E W, van Tilborg, A A G, Abas, C, Orntoft, T F, Zuiverloon, T C M, Malats, N, Zwarthoff, E C & Real, F X 2014, ' Telomerase reverse transcriptase promoter mutations in bladder cancer : high frequency across stages, detection in urine, and lack of association with outcome ', European Urology, vol. 65, no. 2, pp. 360-6 . https://doi.org/10.1016/j.eururo.2013.08.052
European Urology, 65(2), 360-366. Elsevier

BACKGROUND: Hotspot mutations in the promoter of the gene coding for telomerase reverse transcriptase (TERT) have been described and proposed to activate gene expression. OBJECTIVES: To investigate TERT mutation frequency, spectrum, association with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f1fc50aae8bd1a84594197a51d6111
https://pure.eur.nl/en/publications/83d1f81a-b0f0-4fc0-b165-6eae7ba3ef69